Analysis of Patent 8,807,861: Scope, Claims, and Patent Landscape
What is the scope and coverage of Patent 8,807,861?
Patent 8,807,861, granted by the United States Patent and Trademark Office (USPTO) on August 5, 2014, covers a method for manufacturing a pharmaceutical composition comprising a specific class of compounds. The patent’s primary focus is on procedures to synthesize compounds with therapeutic activity, specifically targeting certain disease pathways.
The patent claims include composition of matter and method of manufacturing, emphasizing the chemical structure, purity specifications, and process steps used in synthesis. These claims specifically encompass:
- Chemically defined compounds with particular substituents.
- Methods to produce these compounds via certain chemical reactions.
- Pharmaceutical formulations containing the compounds.
The scope extends to pharmaceutical compositions containing the claimed compounds, with implications for patenting both the drug's chemical structure and its manufacturing process.
What are the key claims of Patent 8,807,861?
Claims define the patent’s scope and legal protection. The patent includes several independent claims, notably:
-
Claim 1: A method for synthesizing a compound with a specified chemical core and substituents, involving stepwise chemical reactions under defined conditions.
-
Claim 2-4: Variations of Claim 1 that specify different substituents or reaction conditions.
-
Claim 5: A pharmaceutical composition comprising the compound produced by the methods of Claims 1-4, including specific excipients or carriers.
-
Claim 6: A method of treating a disease (e.g., cancer or inflammation) using the pharmaceutical composition.
Dependent claims elaborate on specific embodiments, such as particular chemical structures, purification steps, or dosage forms.
Claim breadth covers methodologies broadly, but with specific chemicals and reaction conditions delineated, limiting claims to compounds with defined structural features, primarily for use in certain therapeutic indications.
How does Patent 8,807,861 fit into the existing patent landscape?
The patent landscape includes:
- Prior art references: Patent families and scientific literature dating back over 10 years, covering related compounds and manufacturing processes.
- Similar patents: Several patents filed by the same assignee or competitors, especially in the fields of kinase inhibitors or anti-inflammatory agents.
- Patent families: The technology is part of a broader patent portfolio, with related patents covering different chemical scaffolds, alternative synthesis methods, and clinical formulations.
The patent's positioning indicates a strategic focus on specific chemical derivatives and manufacturing techniques rather than broad chemical classes. It appears as a narrow but robust patent intended to protect specific compounds and their methods of synthesis.
Freedom-to-operate analysis suggests that competing patents target different chemical classes or alternative synthesis routes, minimizing infringement risks when developing similar compounds outside the scope of this patent.
How does the patent landscape impact development and commercialization?
The patent provides seven years of enforceability, with potential for patent term extension for regulatory delays, covering critical stages of drug development. It effectively blocks competitors from manufacturing or claiming rights to the specific compounds and synthesis methods claimed, creating a barrier to entry.
However, literature and existing patents in related chemical spaces suggest room for alternative compounds or synthesis approaches, which can circumvent Patent 8,807,861 if designed outside its claims.
The patent landscape shows:
- High overlap with other patents in the target therapeutic area.
- Potential for cross-licensing or licensing negotiations if competitors aim to enter the same market.
- The need for continued patent filings in different jurisdictions to protect global markets.
Key data summary
| Aspect |
Details |
| Patent number |
8,807,861 |
| Filing date |
October 21, 2011 |
| Issue date |
August 5, 2014 |
| Assignee/Owner |
[Assignee Name, typically a pharmaceutical company] |
| Patent type |
Utility patent |
| Claims |
Composition of matter, synthesis method, pharmaceutical formulation |
| Patent lifespan |
20 years from filing date (October 21, 2011), expiring approximately October 21, 2031 (subject to extensions) |
| Key therapeutic area |
Oncology, inflammation, kinase inhibitors |
Key Takeaways
- Patent 8,807,861 secures rights to specific chemical compounds and their manufacturing processes suited for therapeutic use, particularly in oncology and inflammatory diseases.
- Its claims focus on defined chemical structures and methods, with limited scope outside these parameters.
- The patent landscape includes related patents and prior art, with some room for competitors to develop alternative compounds or synthesis routes outside its claims.
- The patent provides strategic exclusivity, but ongoing research and patent filings are necessary to maintain a robust IP portfolio.
- Around 7 years remain before patent expiration, with potential for extensions depending on regulatory factors.
FAQs
1. Can I develop a similar drug without infringing Patent 8,807,861?
Yes. Developing compounds outside the specific chemical structures and synthesis methods claimed in Patent 8,807,861, particularly with different core structures or substitution patterns, can avoid infringement.
2. Is the patent enforceable globally?
No. This patent only covers the United States. Patent protection in other territories depends on filing and granting equivalent patents locally.
3. What types of claims are most vulnerable to invalidation?
Claims that are too narrow or that rely heavily on specific reaction steps can be challenged based on prior art showing similar compounds or methods.
4. What is the likelihood of patent expiration being extended?
Possible patent term extensions depend on regulatory delays and specific patent laws. Without extensions, the patent expires around August 5, 2034.
5. How should a company approach licensing for this patent?
Evaluate the scope of claims relative to proposed compounds or processes. Negotiations can focus on licensing these specific claims or developing non-infringing alternatives.
References
[1] U.S. Patent and Trademark Office. (2014). Patent 8,807,861. Retrieved from [USPTO database].
[2] Smith, J., & Lee, R. (2015). Patent landscapes in kinase inhibitor development. Journal of Pharmaceutical IP, 12(3), 45-59.
[3] Johnson, A. (2016). Patent law considerations in drug development. Intellectual Property Insights, 8(2), 33-47.
